Hyloris Pharmaceuticals SA (HYL.BR)
EUR 5.8
(-1.36%)
EUR 5.8
(-1.36%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 17.98 Million EUR | 46.79% |
| 2022 | 13.36 Million EUR | 0.21% |
| 2021 | 13.33 Million EUR | 137.86% |
| 2020 | 5.6 Million EUR | 5.81% |
| 2019 | 5.29 Million EUR | -3.57% |
| 2018 | 5.49 Million EUR | 37.96% |
| 2017 | 3.98 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q2 | 4.1 Million EUR | 0.0% |
| 2023 Q3 | 6.05 Million EUR | 47.36% |
| 2023 Q1 | 4.1 Million EUR | 0.23% |
| 2023 FY | 19.61 Million EUR | 46.79% |
| 2023 Q4 | 5.95 Million EUR | -1.69% |
| 2022 Q2 | 5.98 Million EUR | 105.32% |
| 2022 FY | 13.36 Million EUR | 0.21% |
| 2022 Q4 | 4.09 Million EUR | 0.0% |
| 2022 Q3 | 4.09 Million EUR | -31.55% |
| 2022 Q1 | 2.91 Million EUR | -38.54% |
| 2021 FY | 13.33 Million EUR | 137.86% |
| 2021 Q4 | 4.74 Million EUR | 89.84% |
| 2021 Q3 | 2.49 Million EUR | -21.12% |
| 2021 Q2 | 3.16 Million EUR | -27.57% |
| 2021 Q1 | 4.37 Million EUR | 174.58% |
| 2020 Q2 | 2.29 Million EUR | 75.9% |
| 2020 FY | 5.6 Million EUR | 5.81% |
| 2020 Q4 | 1.59 Million EUR | 0.0% |
| 2020 Q1 | 1.3 Million EUR | -38.29% |
| 2020 Q3 | 1.59 Million EUR | -30.71% |
| 2019 Q2 | 484 Thousand EUR | -16.41% |
| 2019 Q3 | 2.11 Million EUR | 337.6% |
| 2019 Q1 | 579 Thousand EUR | 0.0% |
| 2019 FY | 5.29 Million EUR | -3.57% |
| 2019 Q4 | 2.11 Million EUR | 0.0% |
| 2018 FY | 5.49 Million EUR | 37.96% |
| 2017 FY | 3.98 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.17 Million EUR | -330.62% |
| ABIVAX Société Anonyme | 127.37 Million EUR | 85.879% |
| Adocia SA | 15.62 Million EUR | -15.087% |
| Aelis Farma SA | 18.81 Million EUR | 4.421% |
| Biophytis S.A. | 14.33 Million EUR | -25.494% |
| Advicenne S.A. | 8.21 Million EUR | -118.953% |
| genOway Société anonyme | 16.73 Million EUR | -7.46% |
| IntegraGen SA | 5.35 Million EUR | -236.048% |
| Medesis Pharma S.A. | 1.56 Million EUR | -1049.643% |
| Neovacs S.A. | 10.34 Million EUR | -73.896% |
| NFL Biosciences SA | 4.37 Million EUR | -311.192% |
| Plant Advanced Technologies SA | 2.76 Million EUR | -550.56% |
| Quantum Genomics Société Anonyme | 1.71 Million EUR | -946.995% |
| Sensorion SA | 27.05 Million EUR | 33.514% |
| Theranexus Société Anonyme | 3 Million EUR | -498.572% |
| TME Pharma N.V. | 5.49 Million EUR | -227.215% |
| Valbiotis SA | 9.86 Million EUR | -82.258% |
| TheraVet SA | 1.64 Million EUR | -993.891% |
| Valerio Therapeutics Société anonyme | 20.32 Million EUR | 11.481% |
| argenx SE | 1.34 Billion EUR | 98.66% |
| BioSenic S.A. | 7.58 Million EUR | -137.202% |
| Celyad Oncology SA | 8.49 Million EUR | -111.861% |
| DBV Technologies S.A. | 89.4 Million EUR | 79.882% |
| Galapagos NV | 327.98 Million EUR | 94.516% |
| Genfit S.A. | 54.8 Million EUR | 67.179% |
| GeNeuro SA | 14.35 Million EUR | -25.281% |
| Innate Pharma S.A. | 64.57 Million EUR | 72.143% |
| Inventiva S.A. | 120.18 Million EUR | 85.034% |
| MaaT Pharma SA | 21.59 Million EUR | 16.719% |
| MedinCell S.A. | 32.92 Million EUR | 45.365% |
| Nanobiotix S.A. | 58.92 Million EUR | 69.476% |
| Onward Medical N.V. | 20.64 Million EUR | 12.875% |
| Oryzon Genomics S.A. | 18.49 Million EUR | 2.758% |
| OSE Immunotherapeutics SA | 23.58 Million EUR | 23.748% |
| Oxurion NV | 12.21 Million EUR | -47.265% |
| Pharming Group N.V. | 204.24 Million EUR | 91.194% |
| Poxel S.A. | 28.76 Million EUR | 37.469% |
| GenSight Biologics S.A. | 32.66 Million EUR | 44.927% |
| Transgene SA | 31.23 Million EUR | 42.407% |
| Financière de Tubize SA | 114.38 Thousand EUR | -15624.414% |
| UCB SA | 2.94 Billion EUR | 99.388% |
| Valneva SE | 134.92 Million EUR | 86.669% |
| Vivoryon Therapeutics N.V. | 24.69 Million EUR | 27.155% |